The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Summary: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side eff...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2021-12-01
|
| Sarja: | iScience |
| Aiheet: | |
| Linkit: | http://www.sciencedirect.com/science/article/pii/S2589004221014504 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|